Patients 18 to 80 years of age with fasting low-density lipoprotein cholesterol ( LDL-C ) 100 and < 190 mg/dl and Framingham risk scores10 % were randomized ( 1:1:1:1:2:2 ) to oral placebo and subcutaneous ( SC ) placebo biweekly ; oral placebo and SC placebo monthly ; ezetimibe and SC placebo biweekly ; ezetimibe and SC placebo monthly ; oral placebo and evolocumab 140 mg biweekly ; or oral placebo and evolocumab 420 mg monthly .